Whether to Address the Tricuspid Valve During Mitral Surgery
A single patient whose mitral repair is the clear priority, with a second, less severe valve problem making the actual scope of the operation a genuine question.
P.R., a 67-year-old man, spent most of his working life as a welder in a shipyard, retiring eight years ago with the kind of steady hands and unhurried patience the trade demands. Progressive breathlessness over the past year, eventually limiting how far he could walk without stopping, led to an echocardiogram that confirmed what his cardiologist had suspected: severe mitral regurgitation requiring surgical repair.
The same echocardiogram showed something else, incidental to the reason for the study: moderate, not severe, functional tricuspid regurgitation, with mild dilation of the tricuspid annulus. His right ventricular function remains preserved. Nothing about the tricuspid finding is driving his symptoms — the mitral valve is doing that on its own — but it raises a question that has to be settled before, not after, his operation: whether to address the tricuspid valve at the same time.
Guidance on this question has moved toward a lower threshold for concomitant tricuspid intervention during left-sided valve surgery in recent years, driven largely by evidence that moderate functional TR commonly progresses after mitral surgery even when the mitral repair itself succeeds, and that an isolated tricuspid reoperation later carries substantially higher risk than addressing it at the same operation. The threshold is specific: concomitant repair becomes a reasonable option when the tricuspid annulus measures more than 40mm at end-diastole, or more than 21mm per square meter of body surface area. His measures 39mm. Whether a millimeter under the line should be read as not qualifying, or as a valve on its way there, is where the actual disagreement lives. He has no prior cardiac surgery and no other significant comorbidity that would independently argue for keeping today's operation as limited as possible.
How much surgery this operation should actually be
I'd perform tricuspid annuloplasty at the same operation. The evidence on this is fairly consistent: moderate functional TR with annular dilation commonly progresses after mitral surgery even when the repair goes well, and an isolated late tricuspid reoperation carries substantially higher risk than addressing it now, while we're already there. Waiting to see if it worsens means accepting a much harder second operation as the price of being wrong.
I'd want to be more conservative here specifically because his findings sit at the milder end of what that guidance is describing. His TR is moderate, not severe, and at 39mm his annulus sits under the 40mm the recommendation actually specifies — we'd be operating on a criterion he doesn't meet. Adding tricuspid repair extends his bypass time and adds real complexity to an already significant operation, for a valve that may not progress the way the guidance assumes.
That's a fair distinction, and I'd concede this sits right at the edge of where the evidence gets less clean. My own read is that mild-but-present annular dilation is usually the early sign of the exact progression pattern this guidance is meant to preempt, not a reassuring finding on its own — but I recognize this is genuinely a judgment call at the boundary of current guidance, not a case with one clearly correct answer. Neither physician disputed the underlying guidance itself; the disagreement was specifically about where his own findings sit relative to it.
Medical management isn't a real alternative on the table here, and it matters why not. Diuretics relieve the venous congestion functional TR eventually causes, but they don't reduce annular diameter or arrest the progressive dilation driving it — there's no pharmacologic equivalent to an annuloplasty ring the way ACE inhibitors and beta-blockers can meaningfully slow remodeling in a failing left ventricle. That asymmetry is exactly why this guidance shifted toward a mechanical fix instead of a watch-and-treat-symptoms approach: once dilation has started, medication manages the downstream consequences without touching the actual driver.
Concomitant tricuspid annuloplasty performed at the same operation as his mitral repair, based on the surgical team's judgment that the mild annular dilation was trending toward progression rather than representing a stable finding.
The concomitant procedure is validated as having preempted the progression the guidance describes.
The added complexity and bypass time will have been incurred for a valve that, under that reading, might not have needed intervention this soon.
The disagreement here was never resolved by one side conceding the data — both readings of the guidance are defensible for findings this close to its boundary — the team proceeded on the surgeon's judgment while explicitly acknowledging, in the record, that a different reasonable team could have made the opposite call.